Long-acting reversible contraception (LARC) is widely regarded as a transformative advancement in reproductive healthcare. Offering unparalleled efficacy and ease of use, LARC methods such as ...
Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...
A woman in her late 30s presented with a complaint of not being able to palpate the subdermal contraceptive implant in her left arm, which was inserted 6 years earlier. An x-ray revealed a ...
NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development ...
Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for ...
On Tuesday, Vivani Medical Inc (NASDAQ:VANI) announced the publication of positive proof-of-concept weight loss data with OKV-119 to treat feline obesity and diabetes in the peer-reviewed BMC ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results